Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immuneering Corp Cl A
(NQ:
IMRX
)
2.020
+0.590 (+41.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immuneering Corp Cl A
< Previous
1
2
3
4
5
Next >
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
March 12, 2024
Former Chairman, CEO and Founder of ChemoCentryx, Inc.
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
March 11, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
March 06, 2024
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END
Via
FinancialNewsMedia
4 Analysts Have This to Say About Immuneering
August 08, 2023
Via
Benzinga
Expert Ratings for Immuneering
June 26, 2023
Via
Benzinga
Analyst Doubles Immuneering Price Target Citing Initial Data Validation
April 19, 2023
Via
Benzinga
What 7 Analyst Ratings Have To Say About Immuneering
April 19, 2023
Via
Benzinga
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
March 05, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
March 04, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
March 01, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
February 20, 2024
From
Immuneering Corporation
Via
GlobeNewswire
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
February 14, 2024
Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation.
Via
InvestorPlace
Immuneering Announces Participation in February Investor Conferences
February 01, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
December 12, 2023
From
Immuneering Corporation
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 21, 2023
Via
Benzinga
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
October 12, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 04, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the Morgan Stanley Healthcare Conference
September 06, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 03, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
June 05, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the Jefferies Healthcare Conference
May 30, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
April 19, 2023
Via
Benzinga
Immuneering Announces $30 Million Underwritten Offering
April 18, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
April 18, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
From
Immuneering Corporation
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
April 07, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 06, 2023
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
